Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis - Wikidata - wikimedia - TriplyDB

Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis

Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis

http://www.wikidata.org/entity/Q30444430

about

Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier Design strategies and applications of circulating cell-mediated drug delivery systems The Effect of Polymeric Nanoparticles on Biocompatibility of Carrier Red Blood Cells Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis.Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the n Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.Targeted thrombolysis strategies for neuroprotective effect Co-opting biology to deliver drugs Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders.Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes Non-affinity factors modulating vascular targeting of nano- and microcarriers RBC-coupled tPA Prevents Whereas tPA Aggravates JNK MAPK-Mediated Impairment of ATP- and Ca-Sensitive K Channel-Mediated Cerebrovasodilation After Cerebral Photothrombosis Advanced drug delivery systems for antithrombotic agents.Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury.Drug delivery by red blood cells: vascular carriers designed by mother nature.Bio-inspired, bioengineered and biomimetic drug delivery carriers.Vascular targeting of antithrombotic agents.Engineering antiphagocytic biomimetic drug carriers.Carrier erythrocytes: recent advances, present status, current trends and future horizons.Approaches to erythrocyte-mediated drug delivery.Erythrocytes-based synthetic delivery systems: transition from conventional to novel engineering strategies.Engineering of plasminogen activators for targeting to thrombus and heightening thrombolytic efficacy.Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems.Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond.The spatial dynamics of fibrin clot dissolution catalyzed by erythrocyte-bound vs. free fibrinolytics.Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.The cytological observation of immune adherence of porcine erythrocyte.Nanoparticle Properties Modulate Their Attachment and Effect on Carrier Red Blood Cells.

P2860

Q26801300-6226C560-AA66-4754-9C23-2CD589FCD0F7 Q28547179-B2010F78-FC33-4539-9B9A-BF1C7E190C77 Q28550941-45448F1E-92AC-4589-AA0F-8C3B576F31A0 Q30514795-0D6E8E74-A5A2-4E23-BAA0-84E4DC765892 Q33714889-80083E32-0F7A-47E4-B535-4D033D927FAB Q33734359-173CF0E8-7560-4EEA-B9ED-673B767EA1F4 Q33944248-57C9ACED-5511-4208-8077-6444C8D9F826 Q34163191-2BF35AF0-ECE6-4B70-A979-214E08FF881E Q34424045-7E3229CE-004F-4911-8B76-8E09E141EFF9 Q36307742-2DF1F2DF-201F-453A-839C-F870982017C8 Q36381471-E3119003-E2C6-41CE-A85C-44011C77EA0B Q36703526-91C402AE-F502-4BBB-8697-90846842D539 Q36748046-E46CC433-39DF-4207-A0E8-B5B68D2D4F84 Q37132620-959AC626-B2CF-4324-89D2-9AD77DBBDA95 Q37263891-5931B2B3-923B-4ACB-AC0C-CBF4A00B2379 Q37285884-BD488599-653A-4512-A72E-63C807709200 Q37397703-1AF2A049-B2B5-4647-BFEF-21A2134D1978 Q37700751-09A1F83B-32B6-4C82-8935-BB4C24C2F2AD Q37896455-9326CC3A-73CA-4392-A784-FEACF4A2472C Q37902114-BF427852-F9F5-4E4E-862C-3DE50A987DE9 Q38123856-6026CF24-74CF-4615-9590-33D71488D9F5 Q38181182-F7B670C4-B0B1-4F47-A310-E832265287C8 Q38189095-6B2FD80F-A478-401A-84E5-42B7270244D1 Q38218799-1FB74217-3FA0-4B4A-9219-8FB9424279AD Q38527633-02148AED-D819-4E2D-9B7B-8890CD36767E Q38760096-E49D66C7-34DF-4047-8169-2E168744DB0C Q38972974-02CC593E-5D15-4E5E-8B8D-C7D162101347 Q41302329-30428EB0-AEC0-49AC-A9FB-3B2B2C10C3E8 Q42028534-77CE801A-FD9D-49DB-844B-41587982210A Q44355392-303187AF-546F-4354-9624-61C9103566D0 Q49351130-5C7707C0-E560-4CF9-9626-70304E0085B4

P2860

Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis

http://www.wikidata.org/entity/Q30444430

description

2006 nî lūn-bûn

@nan

2006 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Human complement receptor type ...... for prophylactic fibrinolysis

@ast

Human complement receptor type ...... for prophylactic fibrinolysis

@en

type

label

Human complement receptor type ...... for prophylactic fibrinolysis

@ast

Human complement receptor type ...... for prophylactic fibrinolysis

@en

prefLabel

Human complement receptor type ...... for prophylactic fibrinolysis

@ast

Human complement receptor type ...... for prophylactic fibrinolysis

@en

P1433

Q30444430-BD0A414A-A3E2-4EF2-A4EB-B75FD4D9434B

P1476

Q30444430-6B4798C2-1CC3-444E-8966-5CD573142DC8

P2093

Q30444430-035BF2D9-E36F-4C61-9AFE-0521617492D7

Q30444430-10872088-4914-4166-8951-B56F9ECFC3FE

Q30444430-16BB7136-03C8-471B-9938-CB7FE14C0ED2

Q30444430-2C28836A-03E4-4CC5-9148-DF05FB4EA20A

Q30444430-4238A88E-5474-4F47-842A-F843D5DE5632

Q30444430-ADD2B358-FAEE-462A-8467-B40B4EF637E6

Q30444430-B3EDFB0B-5CA7-45CC-874B-638A46D67FCB

Q30444430-D38D3C1B-7806-4322-B1EF-A7053093A8CB

Q30444430-E404695E-B0A9-450F-A1EC-E0736B88C507

Q30444430-E97250FB-5455-41C0-8ED4-BB6B78D65EC7

P2860

Q30444430-077B0E86-198C-4ACD-9C82-83C49ED89973

Q30444430-0D223026-1100-4AB1-9552-00119A912041

Q30444430-0DBC0A5B-09E0-415F-829D-172C3BA85751

Q30444430-0F42C84F-CD10-48B8-A36E-A29B4AA9F4EE

Q30444430-12923EA7-4351-45EF-95C7-415EF299E9D4

Q30444430-1B9122E1-5671-4912-B434-7B29DCF59441

Q30444430-22321179-F0B0-4FC8-847E-12C5F9CD2C52

Q30444430-278635F1-DB2D-4301-89C9-1786C75ABBB9

Q30444430-318AACFC-549C-49F9-82B1-00002FF58F5C

Q30444430-3A12D41D-5697-4A04-AEC5-8FBE39022F3B

P304

Q30444430-F409F588-88B7-415E-B3B7-EDFFE629499E

P31

Q30444430-96BCF7E5-3BB5-4B35-A4A0-E161B7B13DA5

P356

Q30444430-0010FC37-8268-428A-98BF-7962E74E54D2

P407

Q30444430-C040A921-1959-4A55-9EAF-4AC5B8C465D0

P433

Q30444430-1489FCBA-C717-4CD2-8A0B-D4FAAFC013E4

P478

Q30444430-89568CF3-86BB-4B64-870A-EC8459E2693B

P577

Q30444430-2C181D38-CE3C-431F-9C7C-FE7EE49FB50A

P5875

Q30444430-B2F7D4D4-AFE9-470E-8559-A73F40DA036E

P698

Q30444430-AA6EFAEF-C83C-4849-B305-4B0E6B487F08

P932

Q30444430-7B504F9C-1EDE-4E61-B125-7898BDFC41B6

P356

BLOOD-2005-11-012336

P1433

P1476

Human complement receptor type ...... for prophylactic fibrinolysis

@en

P2093

Douglas B Cines

http://www.w3.org/2001/XMLSchema#string

Juan-Carlos Murciano

http://www.w3.org/2001/XMLSchema#string

Kristina Danielyan

http://www.w3.org/2001/XMLSchema#string

Kumkum Ganguly

http://www.w3.org/2001/XMLSchema#string

Ronald P Taylor

http://www.w3.org/2001/XMLSchema#string

Sergei Zaitsev

http://www.w3.org/2001/XMLSchema#string

Steven Jones

http://www.w3.org/2001/XMLSchema#string

Steven Pincus

http://www.w3.org/2001/XMLSchema#string

Tatiana Krasik

http://www.w3.org/2001/XMLSchema#string

Vladimir R Muzykantov

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning and expression of a chloride channel-associated protein pICln in human young red blood cells: association with actin

Peripheral arterial disease: pathophysiology, risk factors, and role of antithrombotic therapy

Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin,

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda

Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase

Invasive approaches to treatment of venous thromboembolism

Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment

Antigen-based heteropolymers facilitate, via primate erythrocyte complement receptor type 1, rapid erythrocyte binding of an autoantibody and its clearance from the circulation in rhesus monkeys.

Cross-linked bispecific monoclonal antibody heteropolymers facilitate the clearance of human IgM from the circulation of squirrel monkeys.

P304

1895-1902

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-11-012336

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P577

2006-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7046485

http://www.w3.org/2001/XMLSchema#string

P698

16735601

http://www.w3.org/2001/XMLSchema#string

P932

1895545

http://www.w3.org/2001/XMLSchema#string